Guardion Health Sciences (NASDAQ:GHSI – Get Free Report) and Rocket Pharmaceuticals (NASDAQ:RCKT – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation and profitability.
Profitability
This table compares Guardion Health Sciences and Rocket Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Guardion Health Sciences | 22.79% | -73.69% | -48.17% |
| Rocket Pharmaceuticals | N/A | -54.47% | -47.99% |
Institutional and Insider Ownership
20.2% of Guardion Health Sciences shares are owned by institutional investors. Comparatively, 98.4% of Rocket Pharmaceuticals shares are owned by institutional investors. 1.3% of Guardion Health Sciences shares are owned by insiders. Comparatively, 31.1% of Rocket Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Risk & Volatility
Analyst Ratings
This is a summary of recent ratings and recommmendations for Guardion Health Sciences and Rocket Pharmaceuticals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Guardion Health Sciences | 0 | 1 | 0 | 0 | 2.00 |
| Rocket Pharmaceuticals | 0 | 1 | 8 | 0 | 2.89 |
Rocket Pharmaceuticals has a consensus price target of $52.29, indicating a potential upside of 164.34%. Given Rocket Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe Rocket Pharmaceuticals is more favorable than Guardion Health Sciences.
Valuation and Earnings
This table compares Guardion Health Sciences and Rocket Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Guardion Health Sciences | $12.23 million | 1.10 | $160,000.00 | ($4.02) | -2.62 |
| Rocket Pharmaceuticals | N/A | N/A | -$245.60 million | ($2.87) | -6.89 |
Guardion Health Sciences has higher revenue and earnings than Rocket Pharmaceuticals. Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Guardion Health Sciences, indicating that it is currently the more affordable of the two stocks.
Summary
Rocket Pharmaceuticals beats Guardion Health Sciences on 9 of the 13 factors compared between the two stocks.
About Guardion Health Sciences
Guardion Health Sciences, Inc., a clinical nutrition company, develops and distributes clinically supported dietary supplements and medical foods in North America, Europe, and internationally. The company offers GlaucoCetin, a dietary supplement to support mitochondrial function with additional antioxidants to help reduce oxidative stress and increase blood flow throughout the body for enhanced eye support and ocular health; and Lumega-Z, a medical food that replenishes and restores the macular protective pigment. It also provides Viactiv Omega Boost Gel Bites, an omega-3 fish oil dietary supplement. The company distributes medical foods products through e-commerce website, guardionhealth.com. Guardion Health Sciences, Inc. was founded in 2009 and is headquartered in Houston, California.
About Rocket Pharmaceuticals
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.
Receive News & Ratings for Guardion Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardion Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
